Recently in Cell, Dijkstra et al. (2018) introduced a tumor organoid/lymphocyte co-culture-based approach to expand and analyze tumor-specific T cell responses in a patient-specific manner. The platform is applicable for epithelial cancers and may have significant value for clinical translation of novel personalized immunotherapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.stem.2018.08.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enabling immune checkpoint blockade efficacy in T-lymphopenia by restoring CD8 T cell dynamics with IL-7 cytokine therapy.
Front Immunol
January 2025
Department of Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea.
Introduction: T-lymphopenia (TLP) is a frequently observed condition in cancer patients, often exacerbated by conventional chemo/radiotherapy, which impairs the efficacy of subsequent immune checkpoint blockade (ICB) therapy. This study aimed to understand the impact of TLP on ICB responsiveness and explore potential therapeutic strategies to enhance antitumor immunity.
Methods: To investigate ICB responsiveness depending on the severity of TLP, first, we established TLP mouse models that mimic clinically observed mild and severe TLP through thymectomy and anti-Thy1-induced peripheral T cell depletion.
Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system.
Front Immunol
December 2024
Research and Development, Miltenyi Biotec, Bergisch Gladbach, Germany.
Recent studies have revealed the potential of tumor-infiltrating lymphocytes (TILs) to treat solid tumors effectively and safely. However, the translation of TIL therapy for patients is still hampered by non-standardized and laborious manufacturing procedures that are expensive and produce highly variable cellular products. To address these limitations, the CliniMACS Prodigy Tumor Reactive T cell (TRT) Process has been developed.
View Article and Find Full Text PDFMyeloid effector cells in cancer.
Cancer Cell
December 2024
Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands. Electronic address:
The role of myeloid cells in tumor immunity is multifaceted. While dendritic cells support T cell-mediated tumor control, the highly heterogenous populations of macrophages, neutrophils, and immature myeloid cells were generally considered immunosuppressive. This view has led to effective therapies reinvigorating tumor-reactive T cells; however, targeting the immunosuppressive effects of macrophages and neutrophils to boost the cancer immunity cycle was clinically less successful.
View Article and Find Full Text PDFSingle-cell profiling of acral melanoma infiltrating lymphocytes reveals a suppressive tumor microenvironment.
Sci Transl Med
December 2024
Department of Pathology, Sapporo Medical University School of Medicine, 060-8556 Sapporo, Hokkaido, Japan.
Acral lentiginous melanoma (ALM) is the most common melanoma subtype in non-Caucasians. Despite advances in cancer immunotherapy, current immune checkpoint inhibitors remain unsatisfactory for ALM. Hence, we conducted comprehensive immune profiling using single-cell phenotyping with reactivity screening of the T cell receptors of tumor-infiltrating T lymphocytes (TILs) in ALM.
View Article and Find Full Text PDFCancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome.
Res Sq
November 2024
Insitute of Cancer Research.
T cell immune tolerance is established in part through the activity of the Auto-immune Regulator (AIRE) transcription factor in the medullary Thymic Epithelial Cells (mTEC) of the thymus. AIRE induces expression of SELF peripheral tissue-specific antigens for presentation to naïve T cells to promote activation/deletion of potentially autoreactive T cells. We show, for the first time to our knowledge, that tumors mimic the role of AIRE in mTEC to evade immune rejection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!